Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.

Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ.

Prostate. 2019 Nov 19. doi: 10.1002/pros.23922. [Epub ahead of print]

PMID:
31742767
2.

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice.

Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A, Pei J, Rafique A, Poueymirou W, Martin J, MacDonald D, Olson WC, Murphy A, Ioffe E, Thurston G, Mohrs M.

Mol Cancer Ther. 2019 Nov;18(11):2051-2062. doi: 10.1158/1535-7163.MCT-18-1376. Epub 2019 Aug 8.

PMID:
31395688
3.

A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.

Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaau7534. doi: 10.1126/scitranslmed.aau7534.

PMID:
31217340
4.

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.

Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ Jr, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ.

Prostate. 2019 May;79(6):604-613. doi: 10.1002/pros.23765. Epub 2019 Jan 20.

PMID:
30663074
5.

Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.

Zhang Q, Salzler R, Dore A, Yang J, Ma D, Olson WC, Liu Y.

J Proteome Res. 2018 Nov 2;17(11):3932-3940. doi: 10.1021/acs.jproteome.8b00605. Epub 2018 Oct 11.

PMID:
30277784
6.

ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.

Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, Larson SM, Carrasquillo JA.

Mol Pharm. 2018 Jun 4;15(6):2133-2141. doi: 10.1021/acs.molpharmaceut.7b01133. Epub 2018 Apr 30.

7.

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.

Knapp KA, Pires ES, Adair SJ, Mandal A, Mills AM, Olson WC, Slingluff CL Jr, Parsons JT, Bauer TW, Bullock TN, Herr JC.

Oncotarget. 2018 Jan 4;9(10):8972-8984. doi: 10.18632/oncotarget.23944. eCollection 2018 Feb 6.

8.

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA, Smith KT, Olson WC, Fanous IS, Nail CJ, Brenin CM, Hall EH, Slingluff CL Jr.

J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.

9.

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Hutchings CJ, Koglin M, Olson WC, Marshall FH.

Nat Rev Drug Discov. 2017 Sep 1;16(9):661. doi: 10.1038/nrd.2017.173. No abstract available.

PMID:
28860586
10.

Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies.

Shukla GS, Olson WC, Pero SC, Sun YJ, Carman CL, Slingluff CL Jr, Krag DN.

J Transl Med. 2017 Aug 29;15(1):180. doi: 10.1186/s12967-017-1283-8.

11.

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Hutchings CJ, Koglin M, Olson WC, Marshall FH.

Nat Rev Drug Discov. 2017 Sep;16(9):787-810. doi: 10.1038/nrd.2017.91. Epub 2017 Jul 14. Review. Erratum in: Nat Rev Drug Discov. 2017 Sep 1;16(9):661.

PMID:
28706220
12.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. doi: 10.1007/s00262-016-1880-z. Epub 2016 Aug 13.

13.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13.

14.

Myostatin deficiency but not anti-myostatin blockade induces marked proteomic changes in mouse skeletal muscle.

Salzler RR, Shah D, Doré A, Bauerlein R, Miloscio L, Latres E, Papadopoulos NJ, Olson WC, MacDonald D, Duan X.

Proteomics. 2016 Jul;16(14):2019-27. doi: 10.1002/pmic.201600006.

PMID:
27214824
15.

Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.

DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E.

Prostate. 2016 Feb 15;76(3):325-34. doi: 10.1002/pros.23124. Epub 2015 Nov 20.

PMID:
26585210
16.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW.

Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.

17.

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.

Reed CM, Cresce ND, Mauldin IS, Slingluff CL Jr, Olson WC.

Clin Cancer Res. 2015 Sep 1;21(17):3879-87. doi: 10.1158/1078-0432.CCR-15-0233. Epub 2015 May 12.

18.

TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Mauldin IS, Wang E, Deacon DH, Olson WC, Bao Y, Slingluff CL Jr.

Int J Cancer. 2015 Sep 15;137(6):1386-96. doi: 10.1002/ijc.29515. Epub 2015 May 29.

19.

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.

Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.

PMID:
25327986
20.

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.

Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC.

Prostate. 2015 Feb 15;75(3):242-54. doi: 10.1002/pros.22910. Epub 2014 Oct 18.

PMID:
25327687
21.

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.

Dillon PM, Olson WC, Czarkowski A, Petroni GR, Smolkin M, Grosh WW, Chianese-Bullock KA, Deacon DH, Slingluff CL Jr.

J Immunother Cancer. 2014 Jul 15;2:23. doi: 10.1186/2051-1426-2-23. eCollection 2014.

22.

Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.

Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW, Chianese-Bullock KA, Slingluff CL Jr.

Cancer Immunol Immunother. 2014 Aug;63(8):779-86. doi: 10.1007/s00262-014-1551-x. Epub 2014 Apr 23. Erratum in: Cancer Immunol Immunother. 2014 Oct;63(10):1113.

23.

Antibody-drug conjugates targeting prostate-specific membrane antigen.

Olson WC, Israel RJ.

Front Biosci (Landmark Ed). 2014 Jan 1;19:12-33. Review.

PMID:
24389170
24.

T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins.

Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL Jr.

Int J Cancer. 2014 Feb 1;134(3):563-74. doi: 10.1002/ijc.28391.

25.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. doi: 10.1371/journal.pone.0067484. Print 2013.

26.

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.

Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr.

Cancer Immunol Immunother. 2013 Jul;62(7):1149-59. doi: 10.1007/s00262-013-1435-5. Epub 2013 May 9.

27.

A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).

Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM.

Clin Cancer Res. 2013 Aug 1;19(15):4228-38. doi: 10.1158/1078-0432.CCR-13-0002. Epub 2013 May 7.

28.

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Slingluff CL Jr, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ.

Clin Cancer Res. 2013 Jul 1;19(13):3611-20. doi: 10.1158/1078-0432.CCR-12-3919. Epub 2013 Apr 25.

29.

Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile.

Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, Bushman FD.

PLoS One. 2012;7(10):e46966. doi: 10.1371/journal.pone.0046966. Epub 2012 Oct 10.

30.

Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2.

Poignard P, Moldt B, Maloveste K, Campos N, Olson WC, Rakasz E, Watkins DI, Burton DR.

PLoS One. 2012;7(7):e42209. doi: 10.1371/journal.pone.0042209. Epub 2012 Jul 27.

31.

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC.

J Infect Dis. 2012 Sep 1;206(5):706-13. doi: 10.1093/infdis/jis416. Epub 2012 Jun 25.

32.

Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.

Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, Cocco N, Kachare M, Massi E, David KB, Cupo A, Marozsan AJ, Olson WC, Ward AB, Wilson IA, Sanders RW, Moore JP.

J Biol Chem. 2012 Jul 13;287(29):24239-54. doi: 10.1074/jbc.M112.371898. Epub 2012 May 29.

33.

Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.

Coburn GA, Fisch DN, Moorji SM, de Muys JM, Murga JD, Paul D, Provoncha KP, Rotshteyn Y, Han AQ, Qian D, Maddon PJ, Olson WC.

PLoS One. 2012;7(4):e35351. doi: 10.1371/journal.pone.0035351. Epub 2012 Apr 24.

34.

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW.

J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.

35.

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA.

Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.

36.

In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.

Wang X, Ma D, Olson WC, Heston WD.

Mol Cancer Ther. 2011 Sep;10(9):1728-39. doi: 10.1158/1535-7163.MCT-11-0191. Epub 2011 Jul 12.

37.

Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11440-5. doi: 10.1073/pnas.1101414108. Epub 2011 Jun 27.

38.

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.

Olson WC, Smolkin ME, Farris EM, Fink RJ, Czarkowski AR, Fink JH, Chianese-Bullock KA, Slingluff CL Jr.

J Transl Med. 2011 Mar 8;9:26. doi: 10.1186/1479-5876-9-26.

39.

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.

40.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.

41.

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.

Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW.

Virology. 2010 Jun 5;401(2):236-47. doi: 10.1016/j.virol.2010.02.019. Epub 2010 Mar 21. Erratum in: Virology. 2010 Oct 10;406(1):162-3.

42.

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA.

Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10.

43.

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, Durso RJ, Parsons TF, Maddon PJ, Moore JP, Olson WC.

Vaccine. 2009 Aug 13;27(37):5120-32. doi: 10.1016/j.vaccine.2009.06.037. Epub 2009 Jun 28.

44.

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.

Virology. 2009 Jun 20;389(1-2):108-21. doi: 10.1016/j.virol.2009.04.001. Epub 2009 May 2.

45.

CCR5 monoclonal antibodies for HIV-1 therapy.

Olson WC, Jacobson JM.

Curr Opin HIV AIDS. 2009 Mar;4(2):104-11. doi: 10.1097/COH.0b013e3283224015. Review.

46.

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.

Molhoek KR, McSkimming CC, Olson WC, Brautigan DL, Slingluff CL Jr.

Cancer Immunol Immunother. 2009 Jun;58(6):867-76. doi: 10.1007/s00262-008-0602-6. Epub 2008 Oct 8.

47.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.

PMID:
18771406
48.

Clinical trials of cancer therapies targeting prostate-specific membrane antigen.

Olson WC, Heston WD, Rajasekaran AK.

Rev Recent Clin Trials. 2007 Sep;2(3):182-90. Review.

PMID:
18474004
49.

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

Chianese-Bullock KA, Irvin WP Jr, Petroni GR, Murphy C, Smolkin M, Olson WC, Coleman E, Boerner SA, Nail CJ, Neese PY, Yuan A, Hogan KT, Slingluff CL Jr.

J Immunother. 2008 May;31(4):420-30. doi: 10.1097/CJI.0b013e31816dad10.

PMID:
18391753
50.

A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

Vujanovic L, Mandic M, Olson WC, Kirkwood JM, Storkus WJ.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6796-806.

Supplemental Content

Loading ...
Support Center